ReviewBioconjugate chemistry2018
Review in Bioconjugate chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 53 citations in OpenAlex.
- Mechanistic insights for the preparation of improved metal-fluoride based radioimaging agents.Chemical science · 2026Article
- Molecular imaging using (nano)probes: cutting-edge developments and clinical challenges in diagnostics.RSC advances · 2025Review
- Sultones for Radiofluorination and Bioconjugation: Fluorine-18 Labeling of Native Proteins and Glycoproteins.ACS omega · 2025Article
- Evaluation of [Molecular imaging and biology · 2025Article
- Article
- Radiotracers for Molecular Imaging of Angiotensin-Converting Enzyme 2.International journal of molecular sciences · 2024Review
- SyntheticRSC medicinal chemistry · 2024Review
- Design of NovelACS medicinal chemistry letters · 2024Article
- Comparison of renal clearance of [European journal of nuclear medicine and molecular imaging · 2023Article
- Thermodynamic and Kinetic Stabilities of Al(III) Complexes with NMolecules (Basel, Switzerland) · 2023Article
- [Frontiers in oncology · 2023Article
- Review
- Development of a Neurotensin-DerivedCancers · 2022Article
- Development of a Radiotracer for PET Imaging of the SNAP Tag.ACS omega · 2022Article
- Labelling via [AlPharmaceuticals (Basel, Switzerland) · 2021Article
- State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET.Bioconjugate chemistry · 2021Article
- Radiochemistry, Production Processes, Labeling Methods, and ImmunoPET Imaging Pharmaceuticals of Iodine-124.Molecules (Basel, Switzerland) · 2021Review
- The Radiolabeled HER3 Targeting Molecules for Tumor Imaging.Iranian journal of pharmaceutical research : IJPR · 2021Review
- Reaction of [Frontiers in chemistry · 2021Review
- The Effects of an Albumin Binding Moiety on the Targeting and Pharmacokinetics of an Integrin αMolecular imaging and biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The clinical applications of positron emission tomography (PET) imaging pharmaceuticals have increased tremendously over the past several years since the approval of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.